Halozyme slides on an ear­ly fu­til­i­ty fail­ure for its lead can­cer ther­a­py

Halozyme shares slipped 8% on Thurs­day af­ter the biotech re­port­ed that one of its com­bo stud­ies us­ing PEGPH20 couldn’t clear an ear­ly test for fu­til­i­ty.

In­ves­ti­ga­tors were us­ing a com­bi­na­tion of PEGPH20 plus Folfiri­nox against Folfiri­nox alone on pre­vi­ous­ly un­treat­ed metasta­t­ic pan­cre­at­ic can­cer, a tough chal­lenge for any drug. Now the San Diego-based biotech has halt­ed en­roll­ment as it analy­ses the da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.